ALGS Aligos Therapeutics, Inc. Common Stock

XNAS 10.75 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ALGS $10.75 —
Key stats
$10.75
52-Week Range
$3.98 – $13.69
YTD
+17.74%
Straddle Price
$7.03
P/C Vol Ratio
0.25
Market Cap
$0.0B
Open
$4.98
Day Range
$4.55 – $4.98
Volume
33,001
Prev Close
$4.78
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.39
Cost of Equity (CAPM)11.89%
WACC12.04%
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-238.2%
Book / Price66.7% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-2009.0%
Debt / Equity0.00
Quality Score3/6 — normal (10y DCF)
SMA 50$5.70 (Market Anchor value)
SMA 20 / Bollinger Mid$5.23
Bollinger Width / SMA20445.9% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$17.54
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 34.5× · 7 peers
Peer EV/EBITDA n/a 0% median 18.3× · 8 peers
Peer P/B $31.77 50% median 10.2× · 10 peers
Peer P/S $3.31 50% median 6.6× · 9 peers
Market Anchor (SMA50) $5.70 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
82
List Date
2020-10-16
CIK
0001799448
Next Earnings
2026-11-05 (Pre-Market)
EPS Forecast
($2.43) (2 est.)
Headquarters
South San Francisco, CA
Homepage
https://www.aligos.com

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan4.53%-73.85%106.38%-2.73%-35.21%-11.61%-2.08%
Feb3.87%-25.99%-28.78%43.48%-25.25%-11.57%-7.37%
Mar-22.12%-17.31%-42.12%-13.27%-43.10%6.68%-21.87%
Apr16.91%-40.70%30.04%-19.59%-21.85%-22.61%-9.63%
May2.01%0.00%-11.02%-23.38%-12.34%-6.40%-8.52%
Jun-26.83%-0.82%-18.40%-43.25%37.33%7.85%-7.35%
Jul-13.58%-0.80%-11.00%40.92%-1.49%-22.10%-1.34%
Aug16.94%0.81%-2.16%-4.30%41.42%27.39%13.35%
Sep-6.51%-9.84%-14.14%-27.65%-7.72%-7.55%-12.23%
Oct2.12%-2.78%-25.00%13.46%-19.83%-15.45%*-7.91%
Nov-4.37%-4.76%-6.67%167.12%27.22%--35.71%
Dec-11.45%-1.26%-5.29%54.90%0.22%--7.42%
Total-39.71%-92.24%-60.19%93.86%-65.93%-49.47%-35.61%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $5.23
SMA 50: $5.70
SMA 200: $6.32
Current: $4.65
EMA 12: $5.01
EMA 26: $5.23
MACD: -0.2278 | Signal: -0.0481
BEARISH
ADX (14): 16.44
RANGE
+DI: 11.46
−DI: 23.24

Momentum Oscillators

RSI (14): 33.14
NEUTRAL
Stoch %K: 15.29
Stoch %D: 22.55
Williams %R: -90.83

Volume & Volatility

BB Upper: $5.84
BB Lower: $4.62
NEUTRAL
OBV: 15,763,335
Vol SMA 20: 33,362
Vol ROC: -42.38%
ATR: $0.39
True Range: $0.43
HV 20: 50.2%
HV 30: 46.8%
HV 60: 96.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (confidence level: 6/10)

Key Drivers:

  • Recent positive news headlines regarding Aligos Therapeutics' pipeline advancements and partnerships
  • Bullish momentum signals from MACD and RSI oscillators
  • Weak trend regime indicated by ADX/DMI analysis

Primary Risks:

  • High volatility, potentially leading to increased price swings
  • Beta of 1.36 suggests the stock moves more than the market, increasing risk exposure

Investment Thesis: ALGS presents a moderately bullish opportunity, driven by recent positive news and momentum signals. However, high volatility and beta pose risks that require careful management.

Recent News Sentiment Impact: Positive headlines have contributed to the current bullish momentum, with four consecutive positive news articles driving sentiment.

Technical Analysis

Trend Direction: Short-term: NEUTRAL Medium-term: BULLISH (1-3 months) Long-term: BEARISH (12+ months)

Support/Resistance Levels:

  • Upper band: $7.74
  • Middle band: $6.77
  • Lower band: $5.80

Momentum Signals: RSI interpretation: NEUTRAL (48.78) MACD signal: BULLISH (0.13 / -0.13 / 0.27) Bollinger Bands position: NEUTRAL (signal)

Volume Analysis:

  • Volume SMA 20: 109631.56
  • On-Balance Volume (OBV): 15918579.52
  • Volume Rate of Change: -61.23%

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines, focusing on pipeline advancements and partnerships.

Sentiment Assessment: POSITIVE

Catalyst Identification: Upcoming regulatory approvals and potential breakthroughs in Aligos Therapeutics' pipeline could drive further price increases.

Market Narrative: News sentiment aligns with the bullish momentum signals from MACD and RSI oscillators, supporting a moderately bullish stance.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta >1.2)

Volatility Regime: Current high volatility regime.

Options Market Signals:

  • IV Rank: 0.0% (Low - shows if volatility is historically high/low)
  • Put/call ratio: 0.25 (Bullish sentiment)

Downside Protection: Support levels and risk management considerations are crucial due to the high volatility and beta.

Market Context & Positioning

Sector Performance: ALGS has outperformed its sector peers.

Institutional Activity: Moderate institutional interest suggests potential support for further price increases.

Correlation Analysis: Stock moves relatively independently from the market (R-squared interpretation).

Relative Valuation: Positions within a trading range, making it challenging to establish a clear long-term view.

Key Levels & Action Items

Critical Price Levels:

  • Upper band: $7.74
  • Middle band: $6.77
  • Lower band: $5.80

Breakout/Breakdown Levels: Price above/ below the middle band could trigger significant moves.

Time-Sensitive Catalysts: Upcoming regulatory approvals and potential breakthroughs in Aligos Therapeutics' pipeline could drive further price increases.

Risk Management:

  • Stop-loss levels should be set near support levels (e.g., $6.77)
  • Position sizing considerations should prioritize risk management to navigate high volatility.
Generated
Earnings History
4 of 4 under expected move
Avg Expected Move
227.36%
Avg Actual Move
7.76%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-05-04 Pre-Market 88.97% 3.82% 0.04x Within
2024-08-06 Pre-Market 383.26% 2.78% 0.01x Within
2024-11-06 Pre-Market 383.33% 4.88% 0.01x Within
2025-03-10 Pre-Market 53.90% 19.55% 0.36x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ALGS Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $7.03
7-DTE Move: $7.03
Days to Exp: — (2025-03-21)

Options Flow

Call Volume: 40
Put Volume: 10
P/C Volume: 0.25
BULLISH
Call OI: 783
Put OI: 10
P/C OI: 0.013
Total OI: 793

ATM Options Pricing

ATM Call: $0.03
ATM Put: $7.00
Call %: 0.2%
Put %: 65.1%

Chain Summary

Chain Volume: 50
Chain OI: 793
Last Updated: 3/21/2025
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Mar 10 · No data
30 DTE / 10d —
— pts EXTREME
as of Mar 10 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$7.03Mar 21
Beta Analysis

Risk Metrics

Beta: 1.3952
Alpha: -54.17%
Correlation: 0.2014
R-Squared: 4.1%
Stock Volatility: 88.3%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ALGS
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$62K
0.00%
#3031 of 3138-89.2%13F
Rockefeller Capital Management Family office
Rockefeller family
$58K
0.00%
#3297 of 47290.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ALGS Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 10,252,144 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

32 filers2,492,833 shares$15.09M value24.32% of float
# Filer Shares Value % of Total % of Float Period
1 Deep Track Capital, LP 444,110 $2.56M 16.98% 4.33% 2026-06-30
2 Alyeska Investment Group, L.P. 412,000 $2.38M 15.75% 4.02% 2026-06-30
3 Sio Capital Management, LLC 327,237 $1.89M 12.51% 3.19% 2026-06-30
4 Vanguard Group Inc Custodian 200,395 $1.87M 12.37% 1.95% 2025-12-31
5 Marshall Wace, LLP Custodian 246,579 $1.42M 9.43% 2.41% 2026-06-30
6 Woodline Partners LP 177,362 $1.02M 6.78% 1.73% 2026-06-30
7 Vanguard Capital Management LLC 175,543 $1.01M 6.71% 1.71% 2026-06-30
8 BAKER BROS. ADVISORS LP 83,055 $479.23K 3.17% 0.81% 2026-06-30
9 HHLR ADVISORS, LTD. 76,247 $439.94K 2.91% 0.74% 2026-06-30
10 D. E. Shaw & Co., Inc. Custodian 66,463 $383.49K 2.54% 0.65% 2026-06-30
11 UBS Group AG Custodian 59,986 $346.12K 2.29% 0.59% 2026-06-30
12 Geode Capital Management, LLC Custodian 47,173 $272.32K 1.80% 0.46% 2026-06-30
13 Jane Street Group, LLC Custodian 32,402 $186.96K 1.24% 0.32% 2026-06-30
14 BlackRock, Inc. Custodian 30,292 $174.78K 1.16% 0.30% 2026-06-30
15 Vanguard Fiduciary Trust Co 28,612 $165.09K 1.09% 0.28% 2026-06-30
16 Dimensional Fund Advisors LP Custodian 21,044 $121.42K 0.80% 0.21% 2026-06-30
17 Verition Fund Management LLC 18,887 $108.98K 0.72% 0.18% 2026-06-30
18 Trexquant Investment LP 12,339 $71.20K 0.47% 0.12% 2026-06-30
19 RENAISSANCE TECHNOLOGIES LLC 10,800 $62.32K 0.41% 0.11% 2026-06-30
20 Rockefeller Capital Management L.P. Custodian 10,000 $57.70K 0.38% 0.10% 2026-06-30
21 Federation des caisses Desjardins du Quebec Custodian 4,650 $26.83K 0.18% 0.05% 2026-06-30
22 Golden State Wealth Management, LLC 2,674 $15.43K 0.10% 0.03% 2026-06-30
23 Royal Bank of Canada Custodian 2,125 $12.00K 0.08% 0.02% 2026-06-30
24 Citigroup Inc. Custodian 1,808 $10.43K 0.07% 0.02% 2026-06-30
25 Tower Research Capital LLC (TRC) Custodian 359 $2.07K 0.01% <0.01% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

ALGS Insider Trading (Form 4)

Latest: 2026-06-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-29 Margarita Chavez Director Grant (A) +5,860 opt — EDGAR
2026-06-29 Bridget A Martell Director Grant (A) +5,860 opt — EDGAR
2026-06-29 Heather Preston Director Grant (A) +5,860 opt — EDGAR
2026-06-29 Carole Nuechterlein Director Grant (A) +5,860 opt — EDGAR
2026-06-29 Peter Hirth Director Grant (A) +5,860 opt — EDGAR
2026-06-29 James Paul Scopa Director Grant (A) +5,860 opt — EDGAR
2026-03-11 Julian A. Symons See Remarks Grant (A) +23,310 opt — EDGAR
2026-03-11 Nikhil Aneja Principal Accounting Officer Grant (A) +9,450 opt — EDGAR
2026-03-11 Lawrence Blatt President and CEO Grant (A) +105,840 opt — EDGAR
2026-03-11 Lesley Ann Calhoun See Remarks Grant (A) +37,485 opt — EDGAR
2025-07-18 Lawrence Blatt President and CEO Grant (A) +179,800 opt — EDGAR
2025-07-18 Julian A. Symons See Remarks Grant (A) +16,000 opt — EDGAR
2025-07-18 Lesley Ann Calhoun See Remarks Grant (A) +40,185 opt — EDGAR
2025-06-26 Margarita Chavez Director Grant (A) +5,860 opt — EDGAR
2025-06-26 Bridget A Martell Director Grant (A) +5,860 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ALGS Insider Holdings

4 insiders · @ $4.65
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Carole Nuechterlein Director 441,038 $2.05M $6.00M 9 2026-06-29
2 Lawrence Blatt President and CEO 78,440 $364.7K $0 13 2026-03-11
3 Julian A. Symons See Remarks 15,763 $73.3K $0 12 2026-03-11
4 James Paul Scopa Director 7,323 $34.1K $0 8 2026-06-29
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ALGS Board & Officers

As of SEC filings through Jun 29, 2026

Directors 7

Officers 4

  • Lawrence Blatt · President and CEO · listed since Mar 2025
  • Julian A. Symons · Executive Vice President, Chief Scientific Officer · since Oct 15, 2020
  • Lesley Ann Calhoun · Chief Operating Officer and Chief Financial Officer · listed since Mar 2025
  • Nikhil Aneja · Principal Accounting Officer · since Jan 29, 2026
Changes in the last 10 years (43)
Jan 29, 2026Nikhil Aneja became Principal Accounting Officer
Mar 4, 2025Lesley Ann Calhoun first listed as Chief Operating Officer and Chief Financial Officer in an SEC filing
Mar 4, 2025Lawrence Blatt listed as President and CEO (previously Chief Executive Officer) in SEC filings
Sep 23, 2024Hardean Achneck became Chief Medical Officer
Aug 7, 2024Margarita Chavez became a director
Aug 7, 2024Heather Preston became a director
May 9, 2024The company announced the departure of Matthew W. McClure as Chief Medical Officer in an SEC filing
Feb 28, 2024Carole Nuechterlein no longer listed as a 10% owner in SEC filings
Nov 20, 2023The company announced the departure of Leonid Beigelman as President in an SEC filing
Nov 9, 2023The company announced the departure of Leonid Beigelman from the board in an SEC filing
Oct 27, 2023Lawrence Blatt first listed as a director in an SEC filing
Oct 27, 2023Carole Nuechterlein first listed as a 10% owner in an SEC filing
Oct 25, 2023Roche Holding Ltd became a 10% owner
Oct 25, 2023Roche Finance Ltd became a 10% owner
Apr 27, 2022Matthew W. McClure became Chief Medical Officer
Nov 16, 2021Bridget A Martell became a director
Apr 26, 2021James Paul Scopa became a director
Dec 3, 2020Lesley Ann Calhoun no longer listed as Chief Financial Officer in SEC filings
Oct 22, 2020Wellington Biomedical Innovation Master Investors (Cayman) I L.P. reported in an SEC filing no longer being a 10% owner
Oct 22, 2020Novo Holdings A/S reported in an SEC filing no longer being a 10% owner
Not reported recently (11)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
9 ETFs hold ALGS
9 shown · $1.16M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $724,975 — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $263,332 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $71,815 $1.2B 2026-10-23
4 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $39,813 — 2026-10-23
5 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $30,511 — 2026-10-23
6 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $10,005 — 2026-10-23
7 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $8,867 — 2026-10-23
8 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.00% $6,821 $3.2B 2026-10-23
9 DFSU Dimensional US Sustainability Core 1 ETF Dimensional 0.00% $5,492 $2.4B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-8.79
TTM Revenue
$4.71M
TTM Net Income
$-90.32M
TTM Op. Cash Flow
$-84.72M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$2.83M$-23.04M$-2.21$-23.13M
Q4 '252025-12-31$169.00K$-19.88M$-2.01$-21.75M
Q3 '252025-09-30$741.00K$-31.54M$-3.04$-24.34M
Q2 '252025-06-30$965.00K$-15.86M$-1.53$-15.50M
Q1 '252025-03-31$311.00K$43.09M$-2.11$-20.91M
Q4 '242024-12-31$629.00K$-82.15M$-13.10$-18.40M
Q3 '242024-09-30$1.27M$-19.26M$-3.07$-20.10M
Q2 '242024-06-30$1.06M$5.06M$0.81$-19.49M
Q1 '242024-03-31$986.00K$-34.86M$-5.58$-22.75M
Q4 '232023-12-31$2.68M$-27.89M$0.39$-22.66M
Q3 '232023-09-30$3.24M$-18.04M$-10.37$-20.34M
Q2 '232023-06-30$6.89M$-18.79M$-10.75$-13.62M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.50
P/S
10.13
EV/EBITDA
—
EV/Sales
3.76
ROE
-284.1%
ROA
-139.9%
Div Yield
0.00%
FCF Yield
-177.72%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$47.67M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
708.74K
SI % of Float
12.72%
Days to Cover
14.35
Short Vol Ratio
47.5%
Free Float
5.57M
Float %
89.2%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14